On this page
Deep Dive — Evidence Details
Bottom Line
- ▸Perioperative immunotherapy significantly improves OS (HR 0.65) and EFS (HR 0.58) in resectable stage II-III NSCLC [13].
- ▸Neoadjuvant chemo-immunotherapy is the preferred approach for stage III disease to maximize pathologic response and nodal downstaging [7, 10].
- ▸Surgical resection remains safe post-immunotherapy, though RATS may reduce conversion rates in cases of hilar fibrosis [4, 5].
The addition of immune checkpoint inhibitors (ICIs) to neoadjuvant chemotherapy or as part of a perioperative regimen significantly improves pathologic response and survival in patients with resectable stage II to III non-small cell lung cancer (NSCLC) [7]D5[11]A1b[13]A1b. Current evidence supports neoadjuvant chemo-immunotherapy as a preferred strategy for stage III disease, while both neoadjuvant and adjuvant approaches remain viable for stage II [7]D5. Perioperative immunotherapy has demonstrated a ** reduction in the risk of death** (HR 0.65, 95% CI 0.45-0.93) and a 42% reduction in the risk of disease progression or death (HR 0.58) compared to chemotherapy alone [13]A1b. NNT = 10 to prevent one death at 36 months [13]A1b.
Clinical Efficacy and Nodal Outcomes
In patients with stage III N2 disease, perioperative plus chemotherapy improves the 1-year event-free survival (EFS) rate to 70% compared to 45% with chemotherapy alone (HR 0.46) [10]A1b. Nodal downstaging to node-negative disease occurs in approximately 57% of patients receiving this regimen [10]A1b. Pathologic complete response (pCR) rates are markedly higher with chemo-immunotherapy, reaching 42.5% in some populations compared to 0% with chemotherapy alone [11]A1b.
Surgical Feasibility
Surgery following immunotherapy is feasible and safe, with a postoperative mortality rate of approximately 1% [4]A1a. Robotic-assisted thoracic surgery (RATS) is associated with a significantly lower rate of conversion to open thoracotomy compared to video-assisted thoracoscopic surgery (OR 0.28, 95% CI 0.13-0.65) in the post-immunotherapy setting [5]A1a.
Pearl: Perioperative immunotherapy combined with chemotherapy is now a standard of care for resectable stage II-III NSCLC, offering superior EFS and OS compared to chemotherapy alone [11]A1b[13]A1b. (High, multiple phase 3 RCTs)
| Outcome | Immunotherapy + Chemo | Chemo Alone | Effect Size (HR/OR) |
|---|---|---|---|
| 36-Month OS Rate | 79.3% | 69.3% | HR 0.65 [13]A1b |
| Median EFS | Not Reached | 30.6 months | HR 0.58 [13]A1b |
| pCR Rate (Japanese) | 42.5% | 0% | N/A [11]A1b |
| MPR Rate (Japanese) | 52.5% | 7.1% | OR 14.37 [11]A1b |
Current Evidence and Standard
- ▸Perioperative nivolumab and tislelizumab significantly improve EFS and OS in resectable stage II-III NSCLC compared to chemotherapy alone.
- ▸Neoadjuvant chemoimmunotherapy is preferred for stage III disease, achieving N2 nodal clearance in up to 73.3% of patients.
- ▸Pathological response (MPR/pCR) and nodal status (ypN) are emerging as critical markers to guide the necessity of adjuvant immunotherapy.
The integration of immune checkpoint inhibitors into the (NSCLC) has significantly improved pathological response and survival [4]A1a. Current international consensus from the IASLC and STS emphasizes that multidisciplinary collaboration is essential for determining resectability and selecting between neoadjuvant, adjuvant, or perioperative strategies [7]D5[8]D5. For stage III disease, there is a preference for neoadjuvant chemoimmunotherapy, while for stage II disease, clinical equipoise exists between upfront surgery followed by adjuvant therapy and neoadjuvant or perioperative approaches [7]D5.
Pivotal Trial Evidence
Perioperative plus chemotherapy has demonstrated significant clinical benefit in resectable NSCLC. In the phase 3 CheckMate 77T trial, the 18-month event-free survival (EFS) rate in a Japanese subpopulation was 76.6% with perioperative nivolumab compared to 42.9% with placebo [11]A1b. The pathological complete response (pCR) rate was 42.5% in the nivolumab group versus 0% in the placebo group [11]A1b. In patients with stage III N2 disease, nivolumab improved the 1-year EFS rate to 70% compared to 45% for placebo; NNT = 4 to prevent one event at 1 year [10]A1b. For those with multistation N2 disease, the 1-year EFS rate was 71% with nivolumab versus 46% with placebo [10]A1b.
In the RATIONALE-315 trial, perioperative plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy alone [13]A1b. The 36-month OS rate was 79.3% in the tislelizumab group versus 69.3% in the placebo group; NNT = 10 to prevent one death at 3 years [13]A1b. The median EFS was not reached in the tislelizumab group compared to 30.6 months in the placebo group [13]A1b.
Surgical Feasibility and Outcomes
Neoadjuvant immunotherapy is feasible and safe, though it may increase technical complexity due to hilar fibrosis [4]A1a[5]A1a. A meta-analysis of 27 trials found a pooled postoperative mortality rate of 0.01 and a rate of 10% [4]A1a. Robotic-assisted thoracic surgery (RATS) may offer advantages over video-assisted thoracoscopic surgery ( ) in this setting, showing a significantly lower rate of conversion to thoracotomy and a higher lymph node yield [5]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Adjuvant IO after Neoadjuvant | Required for all patients per trial protocols [10]A1b[11]A1b[13]A1b. | May be unnecessary for patients achieving MPR or ypN0 [17]B3b. | Retrospective [17]B3b | Potential to spare low-risk patients toxicity. |
| of cN3 | Definitive chemoradiotherapy (standard) [16]B3b. | Neoadjuvant ICT followed by surgery [16]B3b. | Cohort study [16]B3b | Surgery may offer OS benefit in pCR/ypN0 responders. |
Pearl: Perioperative immunotherapy significantly improves 3-year OS and pCR rates in resectable NSCLC, with the most robust benefits observed in stage III N2 disease [10]A1b[13]A1b.
| Trial | Intervention | pCR Rate | EFS Rate (Timepoint) | OS Benefit |
|---|---|---|---|---|
| CheckMate 77T [11]A1b | Nivolumab + CT | 42.5% | 76.6% (18-mo) | Not reported (Japanese sub) |
| RATIONALE-315 [13]A1b | Tislelizumab + CT | Reported | NR (Median) | 79.3% (36-mo) |
| CheckMate 77T (N2) [10]A1b | Nivolumab + CT | 22.0% | 70% (1-year) | Not reported |
Applicability and Caveats
- ▸Smoking status is a major determinant of efficacy, with nonsmokers showing no significant EFS benefit in meta-analyses.
- ▸PD-L1 expression ≥ 1% is required for reliable OS benefit, with the highest magnitude of effect seen at TPS ≥ 50%.
- ▸Neoadjuvant TKIs are the standard for EGFR-mutant stage III disease, as they provide superior radiologic response and downstaging compared to immunotherapy.
Patient selection for perioperative immunotherapy depends heavily on smoking status and PD-L1 expression levels. While smokers derive significant benefit from neoadjuvant immunotherapy (HR 0.54, p < 0.001), the benefit in nonsmokers is not statistically significant (HR 0.68, p = 0.055) [18]A1a. PD-L1 expression serves as a critical predictive biomarker; patients with a tumor cell proportion score (TPS) ≥ 50% achieve the greatest event-free survival (EFS) benefit (HR 0.38), whereas those with TPS < 1% show more modest improvements (HR 0.76 to 0.80) [18]A1a[21]A1a. Overall survival (OS) benefits are significant in patients with PD-L1 ≥ 1% (HR 0.62) but remain uncertain in those with PD-L1 < 1% (HR 1.11) [21]A1a.
Genomic and Clinical Subgroups
Immunotherapy is often ineffective as a monotherapy in oncogene-driven tumors. In resectable stage IIIA/IIIB NSCLC with mutations, neoadjuvant targeted therapy with tyrosine kinase inhibitors (TKIs) is preferred, achieving objective response rates of 57% to 80% [20]B2a. Although neoadjuvant TKIs result in rare pathologic complete response (pCR) rates (~3%), they enable surgical downstaging in 40% to 74% of cases [20]B2a. For patients without lymph node involvement (N0), combining ( ) with immune checkpoint inhibitors has shown DFS benefit over SBRT alone (HR 0.17) [22]A1a.
Regional and Nodal Considerations
Efficacy appears consistent across ethnic backgrounds, though the magnitude of benefit varies. In Japanese subpopulations, perioperative (360 mg neoadjuvant; 480 mg adjuvant) improved the 18-month EFS rate to 76.6% compared to 42.9% with placebo [11]A1b. For high-risk stage III N2 disease, perioperative nivolumab improved the 1-year EFS rate to 70% versus 45% for placebo (HR 0.46), with 57% of patients downstaged to node-negative disease [10]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Optimal Cycles | 3 cycles of neoadjuvant immunochemotherapy [23]A1a. | Extended cycles beyond 3 do not significantly improve MPR/pCR [23]A1a. | High | Limits toxicity and surgical delay. |
| Adjuvant Role | Perioperative (neoadjuvant + adjuvant) [10]A1b[21]A1a. | Neoadjuvant-only may suffice for certain pathological responders [24]A1a. | Emerging | Potential to de-escalate therapy. |
Pearl: Immunotherapy benefit is most pronounced in smokers and those with PD-L1 ≥ 50%, while patients with EGFR mutations should prioritize neoadjuvant TKIs due to low pCR rates with immunotherapy [18]A1a[20]B2a[21]A1a.
| PD-L1 Level | EFS Hazard Ratio (HR) | OS Hazard Ratio (HR) |
|---|---|---|
| < 1% | 0.76 to 0.80 | 1.11 (Uncertain) |
| 1-49% | 0.56 | 0.62 (for ≥ 1%) |
| ≥ 50% | 0.38 | 0.62 (for ≥ 1%) |
On the Horizon
- ▸Neoadjuvant toripalimab or nivolumab with chemotherapy shows superior pCR and EFS compared to chemotherapy alone [26].
- ▸Patients with EGFR or ALK mutations face a 5.5-fold higher risk of treatment failure with neoadjuvant ICIs [30].
- ▸Adjuvant immunotherapy after achieving pCR may not provide additional EFS benefit and can increase toxicity [28, 29].
Multidisciplinary consensus is rapidly shifting toward neoadjuvant and perioperative strategies as evidence for long-term survival emerges [7]D5[8]D5. While neoadjuvant chemo-immunotherapy is preferred for stage III disease, clinical equipoise remains for stage II between upfront surgery and neoadjuvant approaches [7]D5. Recent network meta-analyses suggest that toripalimab combined with chemotherapy may offer the most significant improvement in event-free survival (EFS) (HR 0.40; 95% CI, 0.28-0.58) and pathologic complete response (pCR) (OR 32.89; 95% CI, 7.88-137.32) [26]A1a. plus chemotherapy has also demonstrated a notable overall survival (OS) benefit (HR 0.62; 95% CI, 0.36-1.07) [26]A1a.
Emerging Biomarkers and Patient Selection
Efficacy appears highly dependent on tumor characteristics and smoking status. Neoadjuvant immunotherapy significantly benefits smokers (HR 0.54, p < 0.001) but has not shown statistically significant benefit in nonsmokers (HR 0.68, p = 0.055) [18]A1a. Furthermore, the degree of EFS benefit correlates with PD-L1 expression: patients with TPS ≥ 50% achieve the greatest reduction in risk (HR 0.38) compared to those with TPS < 1% (HR 0.76) [18]A1a.
Actionable Genomic Alterations (AGAs)
Evidence suggests that patients with EGFR or ALK alterations may be poor candidates for neoadjuvant immune checkpoint inhibitors (ICIs). Tumors with AGAs have a higher risk of treatment failure (HR 5.51, 95% CI: 1.68 to 18.1) and a shorter median time to failure of 24.7 months compared to those without AGAs [30]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Adjuvant ICI after pCR | Adjuvant ICI may not be necessary if pCR/MPR is achieved [28]A1a. | Perioperative (sandwich) regimens are standard in many trials [29]A1a. | Moderate | Potential to reduce toxicity and cost [27]A1a. |
| Timing of ICI | Neoadjuvant/perioperative preferred for OS [27]A1a. | Adjuvant-only lacks significant OS benefit in some meta-analyses [27]A1a. | High | Shift toward pre-operative initiation. |
Pearl: Neoadjuvant chemo-immunotherapy is the emerging standard for stage III NSCLC, with the greatest benefits observed in smokers and those with high PD-L1 expression [7]D5[18]A1a.**
| Regimen | Primary Benefit | Effect Size (95% CI) |
|---|---|---|
| Toripalimab + Chemo | Highest pCR Rate | OR 32.89 (7.88-137.32) [26]A1a |
| Nivolumab + Chemo | Overall Survival | HR 0.62 (0.36-1.07) [26]A1a |
| Pembrolizumab + Chemo | R0 Resection Rate | OR 2.15 (1.30-3.56) [26]A1a |
| Durvalumab + Chemo | Lowest Grade 3+ AE | OR 1.05 (0.79-1.38) [26]A1a |
References
- [1]
Kidane B, Bott M, Spicer J et al.. “The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.” The Journal of thoracic and cardiovascular surgery (2023). PMID: 37306641 ↗
L5GUIDELINECited in: Bottom Line, Current Evidence and Standard, On the Horizon - [2]
Scherpereel A, Martin E, Brouchet L et al.. “Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2023). PMID: 36682142 ↗
L5GUIDELINECited in: Bottom Line, Current Evidence and Standard, On the Horizon - [3]
. “[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2025). PMID: 40796288 ↗
L5GUIDELINECited in: Bottom Line, Current Evidence and Standard - [4]
Bertoglio P, Gallina FT, Balzani E et al.. “Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42000405 ↗
L1SR_OBSCited in: Bottom Line, Current Evidence and Standard - [5]
Barbosa S, de Siqueira Silva A, Rodrigues LB. “Robotic-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer after neoadjuvant immunotherapy: a systematic review and meta-analysis.” Journal of robotic surgery (2026). PMID: 41931195 ↗
L1SR_OBSCited in: Bottom Line, Current Evidence and Standard - [6]
Liu W, Feng Z, Zhang M et al.. “Predicting neoadjuvant immunotherapy efficacy with machine learning models in non-small cell lung cancer: A systematic review and meta analysis.” International journal of medical informatics (2026). PMID: 41719848 ↗
L1SR_OBSCited in: Bottom Line, Current Evidence and Standard - [7]
Spicer JD, Cascone T, Wynes MW et al.. “Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024). PMID: 38901648 ↗
L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon - [8]
Kim SS, Cooke DT, Kidane B et al.. “The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer.” The Annals of thoracic surgery (2024). PMID: 39424119 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard, On the Horizon - [9]
Mitome N, Hamada A, Wakabayashi M et al.. “A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).” Clinical lung cancer (2026). PMID: 42107198 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [10]
Provencio M, Awad MM, Spicer JD et al.. “Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.” Nature cancer (2026). PMID: 41507539 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats - [11]
Tanaka F, Watanabe Y, Sugawara S et al.. “Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.” Cancer science (2025). PMID: 41431434 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats - [12]
Cuppens K, Wiesweg M, Baas P et al.. “Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).” European journal of cancer (Oxford, England : 1990) (2025). PMID: 41389771 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats - [13]
Wang C, Wang W, Liu H et al.. “Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41344593 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [14]
Martin LW, Wang X, Kozono D et al.. “CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 41880691 ↗
L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard - [15]
Yan Y, Han Y, Niu Z et al.. “Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial.” Annals of surgical oncology (2026). PMID: 41880079 ↗
L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard - [16]
Zhai W, Liang D, Yu X et al.. “Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 41980306 ↗
L3COHORTCited in: Current Evidence and Standard - [17]
Pan Y, Sun C, Xu H et al.. “Pathologic response and nodal status guide adjuvant immunotherapy in non-small cell lung cancer after neoadjuvant chemoimmunotherapy: An eastern Asian cohort study.” The Journal of thoracic and cardiovascular surgery (2026). PMID: 41765326 ↗
L3COHORTCited in: Current Evidence and Standard - [18]
Zhang W, Dai T, Wang D et al.. “Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials.” BMC cancer (2024). PMID: 39696048 ↗
L1SR_MA_RCTCited in: Applicability and Caveats, On the Horizon - [19]
de Moraes FCA, Pasqualotto E, de Oliveira Rodrigues ALS et al.. “Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials.” European journal of clinical pharmacology (2024). PMID: 39542906 ↗
L1SR_MA_RCTCited in: Applicability and Caveats - [20]
Teodonio L, Peritore V, Andreetti C. “Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.” Updates in surgery (2025). PMID: 40996635 ↗
L2SR_OBSCited in: Applicability and Caveats - [21]
Zhang Z, Lin Y, Chen S. “Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 40463367 ↗
L1SR_OBSCited in: Applicability and Caveats - [22]
Yang X, Xing Z, Long S et al.. “Comparative effectiveness for early-stage NSCLC without lymph node involvement based on prospective studies.” International journal of surgery (London, England) (2025). PMID: 40434735 ↗
L1SR_OBSCited in: Applicability and Caveats - [23]
Liu Y, Long J, Deng H et al.. “Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis.” Frontiers in immunology (2025). PMID: 40213564 ↗
L1SR_OBSCited in: Applicability and Caveats - [24]
Nuccio A, Salomone F, Servetto A et al.. “Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.” Journal of the National Cancer Institute (2025). PMID: 40210599 ↗
L1SR_OBSCited in: Applicability and Caveats - [25]
. “[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2023). PMID: 37460438 ↗
L5GUIDELINECited in: On the Horizon - [26]
Chen K, Wang X, Yue R et al.. “Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials.” Frontiers in immunology (2024). PMID: 39416776 ↗
L1SR_MA_RCTCited in: On the Horizon - [27]
Patel AJ, Hemead H, Law J et al.. “Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials.” European journal of cancer (Oxford, England : 1990) (2024). PMID: 39551030 ↗
L1SR_OBSCited in: On the Horizon - [28]
Marinelli D, Nuccio A, Di Federico A et al.. “Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024). PMID: 39389220 ↗
L1SR_OBSCited in: On the Horizon - [29]
Han Y, Xiao X, Qin T et al.. “Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.” Cancer immunology, immunotherapy : CII (2024). PMID: 39382658 ↗
L1SR_OBSCited in: On the Horizon - [30]
Zhou N, Leung CH, William WN et al.. “Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.” Journal for immunotherapy of cancer (2024). PMID: 39448200 ↗
L2RCTCited in: On the Horizon - [31]
Ross HJ, Kozono D, Wang XF et al.. “Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 39052256 ↗
L2RCTCited in: On the Horizon - [32]
Papaporfyriou A, Bartziokas K, Apessos I et al.. “Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review.” Current oncology (Toronto, Ont.) (2024). PMID: 39451773 ↗
L5SR_OBSCited in: On the Horizon